Send to

Choose Destination
Sci Rep. 2019 Dec 9;9(1):18639. doi: 10.1038/s41598-019-54867-8.

Increased lifespan, decreased mortality, and delayed cognitive decline in osteoarthritis.

Author information

George Mason University, School of Systems Biology, Manassas, VA, 22030, USA.
Neurocombinatorix, 5902 Mount Eagle Dr, Suite 1103, Alexandria, VA, 22303, USA.
George Mason University, School of Systems Biology, Manassas, VA, 22030, USA.
Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russia.


In absence of therapies targeting symptomatic dementia, better understanding of the biology underlying a cognitive decline is warranted. Here we present the results of a meta-analysis of the impact of osteoarthritis (OA) on cognitive decline and overall mortality. Across 7 independent datasets obtained in studies of populations in the USA, EU and Australia (NBER, NSHAP, TILDA, NACC, Kaiser Permanente, GRIM BOOKS, OAI, with a total of >7 × 107 profiles), OA cohorts demonstrated higher cognitive scores, later dementia onset as well as longer lifespan and lower age-specific all-cause mortality. Moreover, generalized OA with multiple localizations is associated with more significant reduction of mortality and dementia than a singly localized OA or no arthritis. In OA patients with younger ages, all-cause mortality was disproportionally reduced as compared to that in controls, while exponential term of Gompert'z hazard function was increased, accelerating mortality accrual at later ages. Up to 8-10% of poly-osteoarthritic patients are predicted and observed to reach centenarian lifespan, while in matched non-OA population the same benchmark is reached by less than 1% of patients. These results point at a possibility of life-extending and cognition preserving impacts of OA-conditioned immune system.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center